Literature DB >> 11080164

Regulation of p53 activity in nuclear bodies by a specific PML isoform.

V Fogal1, M Gostissa, P Sandy, P Zacchi, T Sternsdorf, K Jensen, P P Pandolfi, H Will, C Schneider, G Del Sal.   

Abstract

Covalent modification of the promyelocytic leukaemia protein (PML) by SUMO-1 is a prerequisite for the assembly of nuclear bodies (NBs), subnuclear structures disrupted in various human diseases and linked to transcriptional and growth control. Here we demonstrate that p53 is recruited into NBs by a specific PML isoform (PML3) or by coexpression of SUMO-1 and hUbc9. NB targeting depends on the direct association of p53, through its core domain, with a C-terminal region of PML3. The relocalization of p53 into NBs enhances p53 transactivation in a promoter-specific manner and affects cell survival. Our results indicate the existence of a cross-talk between PML- and p53-dependent growth suppression pathways, implying an important role for NBs and their resident proteins as modulators of p53 functions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11080164      PMCID: PMC305840          DOI: 10.1093/emboj/19.22.6185

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  52 in total

Review 1.  The transcriptional role of PML and the nuclear body.

Authors:  S Zhong; P Salomoni; P P Pandolfi
Journal:  Nat Cell Biol       Date:  2000-05       Impact factor: 28.824

2.  p53 is involved in the p120E4F-mediated growth arrest.

Authors:  P Sandy; M Gostissa; V Fogal; L D Cecco; K Szalay; R J Rooney; C Schneider; G Del Sal
Journal:  Oncogene       Date:  2000-01-13       Impact factor: 9.867

3.  PML regulates p53 acetylation and premature senescence induced by oncogenic Ras.

Authors:  M Pearson; R Carbone; C Sebastiani; M Cioce; M Fagioli; S Saito; Y Higashimoto; E Appella; S Minucci; P P Pandolfi; P G Pelicci
Journal:  Nature       Date:  2000-07-13       Impact factor: 49.962

4.  PML is induced by oncogenic ras and promotes premature senescence.

Authors:  G Ferbeyre; E de Stanchina; E Querido; N Baptiste; C Prives; S W Lowe
Journal:  Genes Dev       Date:  2000-08-15       Impact factor: 11.361

5.  Role of SUMO-1-modified PML in nuclear body formation.

Authors:  S Zhong; S Müller; S Ronchetti; P S Freemont; A Dejean; P P Pandolfi
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

6.  The p66shc adaptor protein controls oxidative stress response and life span in mammals.

Authors:  E Migliaccio; M Giorgio; S Mele; G Pelicci; P Reboldi; P P Pandolfi; L Lanfrancone; P G Pelicci
Journal:  Nature       Date:  1999-11-18       Impact factor: 49.962

7.  c-Jun and p53 activity is modulated by SUMO-1 modification.

Authors:  S Muller; M Berger; F Lehembre; J S Seeler; Y Haupt; A Dejean
Journal:  J Biol Chem       Date:  2000-05-05       Impact factor: 5.157

8.  Nijmegen breakage syndrome disease protein and MRE11 at PML nuclear bodies and meiotic telomeres.

Authors:  D B Lombard; L Guarente
Journal:  Cancer Res       Date:  2000-05-01       Impact factor: 12.701

9.  The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR.

Authors:  H de Thé; C Lavau; A Marchio; C Chomienne; L Degos; A Dejean
Journal:  Cell       Date:  1991-08-23       Impact factor: 41.582

10.  Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML.

Authors:  A Kakizuka; W H Miller; K Umesono; R P Warrell; S R Frankel; V V Murty; E Dmitrovsky; R M Evans
Journal:  Cell       Date:  1991-08-23       Impact factor: 41.582

View more
  111 in total

1.  SUMO-1 modification required for transformation by adenovirus type 5 early region 1B 55-kDa oncoprotein.

Authors:  C Endter; J Kzhyshkowska; R Stauber; T Dobner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

2.  PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies.

Authors:  S Sachdev; L Bruhn; H Sieber; A Pichler; F Melchior; R Grosschedl
Journal:  Genes Dev       Date:  2001-12-01       Impact factor: 11.361

3.  Higher order arrangement of the eukaryotic nuclear bodies.

Authors:  I-Fan Wang; Narsa M Reddy; C-K James Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-02       Impact factor: 11.205

4.  Impairment of p53 acetylation, stability and function by an oncogenic transcription factor.

Authors:  Alessandra Insinga; Silvia Monestiroli; Simona Ronzoni; Roberta Carbone; Mark Pearson; Giancarlo Pruneri; Giuseppe Viale; Ettore Appella; PierGiuseppe Pelicci; Saverio Minucci
Journal:  EMBO J       Date:  2004-02-19       Impact factor: 11.598

5.  Functions of the Epstein-Barr virus EBNA1 protein in viral reactivation and lytic infection.

Authors:  Nirojini Sivachandran; Xueqi Wang; Lori Frappier
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

6.  Resistance to rabies virus infection conferred by the PMLIV isoform.

Authors:  Danielle Blondel; Sabrina Kheddache; Xavier Lahaye; Laurent Dianoux; Mounira K Chelbi-Alix
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

Review 7.  Tied up in loops: positive and negative autoregulation of p53.

Authors:  Xin Lu
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

8.  SIRT1 stabilizes PML promoting its sumoylation.

Authors:  M Campagna; D Herranz; M A Garcia; L Marcos-Villar; J González-Santamaría; P Gallego; S Gutierrez; M Collado; M Serrano; M Esteban; C Rivas
Journal:  Cell Death Differ       Date:  2010-06-25       Impact factor: 15.828

Review 9.  The role of post-translational modifications in fine-tuning BLM helicase function during DNA repair.

Authors:  Stefanie Böhm; Kara Anne Bernstein
Journal:  DNA Repair (Amst)       Date:  2014-08-24

Review 10.  Nuclear microenvironment in cancer diagnosis and treatment.

Authors:  Rossanna C Pezo; Robert H Singer
Journal:  J Cell Biochem       Date:  2008-08-15       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.